Description
This is a Phase 3, Multicenter, Double-blind, Randomized, Placebo-Controlled Trial to evaluate the efficacy of Infigratinib in adult patients with invasive urothelial carcinoma with susceptible FGFR3 genetic alterations (mutations, and gene fusions or translocations)who are within 120 days following nephrouretectomy,distal uretectomy, or cystectomy and ineligible for cisplatin-based (neo) adjuvant chemotherapy or with residual disease after neoadjuvant therapy.
NCT: NCT04197986
